Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 7Triple Negative Breast Neoplasms 3Melanoma 2Lung Neoplasms 2Neoplasms 1Kidney Neoplasms 1Disease Progression 1Colorectal Neoplasms 1Colonic Neoplasms 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 4Nivolumab 3Itraconazole 2tucatinib 1tremelimumab 1regorafenib 1pertuzumab 1lenvatinib 1larotrectinib 1durvalumab 1cemiplimab 1brigimadlin 1aflibercept 1Trastuzumab 1Ritonavir 1Paclitaxel 1Fulvestrant 1Clinical Trials, Phase II as Topic 1Carboplatin 1Capecitabine 1Antibodies 1AZD9833 1AZD5305 1AZD 6244 1ARX788 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × AZD 6244 × Breast × Clear all
NCT02586987 2019-11-18

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
58 enrolled
BreastDermatologicGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡